“Our RAS-targeting franchise continues to advance rapidly, with multiple important clinical milestones approaching,” said Jonathan Lim, Erasca’s (ERAS) chairman, CEO, and co-founder. “A U.S. patent was issued that covers the composition of matter for our potential best-in-class pan-RAS molecular glue ERAS-0015, the first of several patents we anticipate may be issued, which would strengthen the intellectual property surrounding our differentiated RAS portfolio. We also reinforced our scientific leadership with the promotion of Robert Shoemaker, Ph.D., to chief scientific officer. As a core member of Erasca’s founding team, Robert has been instrumental in shaping our research strategy since company inception.”
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ERAS:
- Erasca price target raised to $6 from $4 at Stifel
- Erasca announces issuance of U.S. patent covering ERAS-0015
- Erasca, Inc. Advances with Promising Phase 1 Study on ERAS-4001
- Erasca, Inc. Advances in Cancer Treatment with ERAS-0015 Study
- Erasca’s SEACRAFT-2 Study: A Promising Step in Melanoma Treatment